

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

[Patient & Family Resources](#) & [Treatment](#)

[Refer a Patient](#)

The Marc Ladanyi Lab

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)




Marc Ladanyi, MD

The research program in this laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets. Dr. Ladanyi also co-directs (with Chris Sander) the Genome Data Analysis Center at Memorial Sloan Kettering, which is part of the TCGA project network.

Examples of recent contributions include the validation of *DUSP4* as a driver gene for 8p losses in *EGFR*-mutant lung adenocarcinomas, the establishment of methods for enhanced detection of the *EGFR* T790M secondary mutation in the setting of acquired resistance to *EGFR* inhibitors, the discovery of *BAP1* mutations in mesotheliomas with 3p losses, the identification of novel, recurrent *HEY1-NCOA2* and *KIF5B-RET* fusions in mesenchymal chondrosarcoma and lung adenocarcinoma, respectively,

both based on mining of exon-level expression data, as well as major involvement in the TCGA Network marker papers on the genomics of glioblastoma, ovarian carcinoma, and squamous lung cancer. Ongoing projects are addressing further questions in lung adenocarcinoma, mesothelioma, and several sarcoma types using whole exome and whole transcriptome sequencing, CHIP-seq, Sequenom mass spectrometry genotyping, NanoString expression profiling, RNAi screens, chemical screens, and proteomic approaches.



Ladanyi lab

Featured News

IN THE CLINIC



[A Perfect Match: Molecular Tests Developed at MSK Guide Personalized Treatment for Lung Cancer](#)

For personalized treatment to work, it's important to analyze each person's tumor for genetic mutations and find the best drugs to target those mutations.


IN THE LAB



[What Was MSK's Role in TCGA, the Groundbreaking Cancer Genomic Study?](#)

The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.

IN THE LAB



[Scientists Pinpoint a New Cause of Resistance to EGFR-Targeting Drugs](#)

Multiple copies of a gene called *YES1* appear to be responsible for certain precision drugs losing their effectiveness.

[View All Featured News](#)

Publications Highlights

[Odintsov I, Somwar R, Ladanyi M, Drilon A. \(2021\). ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development. JCO oncology practice, 17\(1\), 15–16.](#)

[Hayashi T, Desmeules P, Smith RS, Drilon A, Somwar R, Ladanyi M. \(2018\). RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 24\(6\), 1436–1447.](#)

[Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaff JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M. \(2018\). YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 115\(26\), E6030–E6038.](#)

[Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M. \(2016\). Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer research, 76\(15\), 4525–4534.](#)

[Spraggon L, Martelotto LG, Hmeljak J, Hitchman TD, Wang J, Wang L, Slotkin EK, Fan PD, Reis-Filho JS, Ladanyi M. \(2017\). Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair. The Journal of pathology, 242\(1\), 102–112.](#)

[View All Publications](#)

People



Marc Ladanyi, MD

Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.
MD, McGill University

[212-639-6369](tel:212-639-6369)

Office Phone

[View physician profile](#)

Physician profile

Members

Lab Alumni

+

Lab Affiliations

+

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

Career Opportunities

[Apply now](#) →

Get in Touch

 [212-639-6369](tel:212-639-6369)

Office Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Marc Ladanyi discloses the following relationships and financial interests:

Paige.AI, Inc.

Equity; Professional Services and Activities (Uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center